Hantz Financial Services, Inc. Krystal Biotech, Inc. Transaction History
Hantz Financial Services, Inc.
- $6.6 Billion
- Q3 2025
A detailed history of Hantz Financial Services, Inc. transactions in Krystal Biotech, Inc. stock. As of the latest transaction made, Hantz Financial Services, Inc. holds 292 shares of KRYS stock, worth $60,198. This represents 0.0% of its overall portfolio holdings.
Number of Shares
292
Previous 181
61.33%
Holding current value
$60,198
Previous $25,000
108.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding KRYS
# of Institutions
329Shares Held
25MCall Options Held
241KPut Options Held
625K-
Black Rock Inc. New York, NY3.95MShares$814 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.79MShares$576 Million0.01% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.78MShares$573 Million6.7% of portfolio
-
State Street Corp Boston, MA1.4MShares$288 Million0.01% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT1.02MShares$210 Million10.94% of portfolio
About Krystal Biotech, Inc.
- Ticker KRYS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,664,300
- Market Cap $5.29B
- Description
- Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing ...